What is the clinical evidence from this study?

Study design: Other. Population: Normotensive. Intervention: Captopril. Primary outcome: Mean arterial pressure (p=<0.01).

What does this research mean for the field?

Oral captopril (25 mg) significantly lowers supine and erect mean arterial pressure and inhibits plasma-converting enzyme for six hours in normotensive sodium-replete individuals without changing heart rate. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To investigate the relationships between the hemodynamic responses to captopril and its effects on sympathetic activity, the renin-angiotensin-aldosterone axis, and plasma-converting enzyme inhibition.

May 1, 1982Journal of Cardiovascular Pharmacology

Effects of Captopril, an Angiotensin-Converting Enzyme Inhibitor, in Normotensive Sodium-Replete Volunteers

Q: What are the key findings of this study?

Oral captopril (25 mg) significantly reduced supine and erect mean arterial pressure in normotensive volunteers (P<0.01) and inhibited plasma-converting enzyme for 6 hours.

Q: What does this research mean for the field?

Oral captopril (25 mg) significantly lowers supine and erect mean arterial pressure and inhibits plasma-converting enzyme for six hours in normotensive sodium-replete individuals without changing heart rate. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Q: What question did this study set out to answer?

To investigate the relationships between the hemodynamic responses to captopril and its effects on sympathetic activity, the renin-angiotensin-aldosterone axis, and plasma-converting enzyme inhibition.

View Full Paper

Ask AI

Bookmark

Key result

Oral captopril reduces mean arterial pressure in normotensive volunteers, inhibiting plasma-converting enzyme for 6 hours.

P<0.01

Why the study?

The relationships between captopril's haemodynamic effects and its impact on sympathetic activity, the renin-angiotensin-aldosterone system, and plasma-converting enzyme activity in normotensive sodium-replete volunteers were investigated.

Does captopril alter haemodynamics and the renin-angiotensin-aldosterone system in normotensive sodium-replete volunteers?

Population

Normotensive sodium-replete volunteers

Comparison

Captopril 25 mg orally vs baseline

Design

Physiological study measuring haemodynamic and biochemical parameters

Follow-up

6 hours

Authors

ASAlan ShepherdPapua New Guinea University of Technology BCBrian C. CampbellRutgers, The State University of New Jersey JRJohn L. ReidLiberty University

Discussion

Member takes

Implication

Should not change practice from normotensive volunteer data; leaves open translation to hypertensive patients.

Key Points

To investigate the relationships between the hemodynamic responses to captopril and its effects on sympathetic activity, the renin-angiotensin-aldosterone axis, and plasma-converting enzyme inhibition.
Administered a single 25 mg oral dose of captopril (SQ 14 225) to normotensive, sodium-replete volunteers.
Assessed supine and erect blood pressure, heart rate, plasma noradrenaline, renin activity, angiotensin I and II, and aldosterone alongside plasma-converting enzyme activity over 6 hours.
Mean arterial pressure decreased significantly in the supine position (89.1 ± 5.9 to 81.1 ± 3.3 mm Hg, p < 0.01) and erect position (98.5 ± 5.5 to 87.4 ± 6.7 mm Hg, p < 0.01) without changes in heart rate.
Plasma-converting enzyme was inhibited for 6 hours, with the extent of inhibition correlating strongly with the degree of blood pressure reduction (r = 0.92, p < 0.001).
Plasma noradrenaline, plasma renin activity, and angiotensin I rose, whereas angiotensin II and aldosterone levels fell following drug administration.

Structured PICO

Does captopril alter haemodynamics and the renin-angiotensin-aldosterone system in normotensive sodium-replete volunteers?

Population

Normotensive, sodium-replete volunteers administered captopril to investigate haemodynamic and neurohormonal effects.

Intervention

Captopril 25 mg orally

Outcome

Haemodynamic effects (mean arterial pressure, heart rate), sympathetic activity, renin-angiotensin-aldosterone system, and plasma-converting enzyme activitysurrogate

Main Result

p-value: p=<0.01

Captopril effectively lowers blood pressure and inhibits converting enzyme in normotensive volunteers, with enzyme inhibition serving as a reliable index of captopril concentration.

Cite This Study

Shepherd et al. (1982) studied Normotensive. Captopril was evaluated on Mean arterial pressure (p=<0.01). Oral captopril (25 mg) significantly reduced supine and erect mean arterial pressure in normotensive volunteers (P<0.01) and inhibited plasma-converting enzyme for 6 hours.

synapsesocial.com/papers/6aa8d91c9477f32da58877f3 https://doi.org/10.1097/00005344-198205000-00007

View Full Paper

Ask AI

Bookmark

Effects of Captopril, an Angiotensin-Converting Enzyme Inhibitor, in Normotensive Sodium-Replete Volunteers

Discussion

Member takes

Implication

Key Points

Structured PICO

Main Result

Cite This Study

Effects of Captopril, an Angiotensin-Converting Enzyme Inhibitor, in Normotensive Sodium-Replete Volunteers

Discussion

Member takes

Implication

Key Points

Structured PICO

Main Result

Cite This Study

Also Consider

Also Consider